Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Tiziana Life Sciences (TLSA) News Today

Tiziana Life Sciences logo
$1.85 -0.05 (-2.63%)
Closing price 04:00 PM Eastern
Extended Trading
$1.83 -0.02 (-1.08%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

TLSA Latest News

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 7.4% - Time to Sell?
August 21, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tiziana-life-sciences-nasdaqtlsa-trading-down-74-time-to-sell-2025-08-20/
Tiziana Life Sciences doses first MSA patient in new trial – ICYMI
August 15, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1076802?snapi
Tiziana Life Sciences Initiates Phase 2a Trial for MSA with Intranasal Foralumab
August 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/tiziana-life-sciences-initiates-phase-2a-trial-for-msa-with-intranasal-foralumab/ar-AA1KwUel
Tiziana Life doses first patient in Phase 2a trial of intranasal foralumab
August 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/tiziana-life-doses-first-patient-in-phase-2a-trial-of-intranasal-foralumab/ar-AA1Kx8RT
Tiziana Life Sciences doses first patient in Phase 2a MSA trial
August 14, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1076705?snapi
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
August 14, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/14/3133472/0/en/tiziana-life-sciences-doses-first-patient-in-phase-2a-trial-of-intranasal-foralumab-for-multiple-system-atrophy.html
Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA
August 11, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1076465?snapi
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
August 11, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/11/3130955/0/en/fda-approves-tiziana-life-sciences-phase-2-ind-for-multiple-system-atrophy.html
Dauntless Investment Group LLC Buys Shares of 1,739,574 Tiziana Life Sciences Ltd (NASDAQ:TLSA)
July 29, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dauntless-investment-group-llc-buys-shares-of-1739574-tiziana-life-sciences-ltd-nasdaqtlsa-2025-07-29/
Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment
July 21, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1075118?snapi
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
July 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/21/3118603/0/en/tiziana-life-sciences-announces-immunologic-analysis-of-nasal-foralumab-in-moderate-alzheimer-s-patient.html
Tiziana Life Sciences Ltd (TLSA) - Yahoo Finance
July 11, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TLSA/news/
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 2.6% - Here's Why
July 9, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tiziana-life-sciences-nasdaqtlsa-stock-price-down-26-heres-why-2025-07-09/
Tiziana Life Sciences (NASDAQ:TLSA) Trading 5.8% Higher - Time to Buy?
June 17, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tiziana-life-sciences-nasdaqtlsa-trading-58-higher-time-to-buy-2025-06-17/
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting
June 13, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4794796-tiziana-scope-of-foralumab-goes-beyond-that-of-multiple-sclerosis-targeting
Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing
June 13, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1072967?snapi
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
June 13, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/13/3099102/0/en/tiziana-life-sciences-expands-phase-2-clinical-trial-of-intranasal-foralumab-with-commencement-of-first-patient-dosing-at-weill-cornell-multiple-sclerosis-center.html
Tiziana Life Sciences to Present at the Bio International Convention
June 13, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/13/3099003/0/en/tiziana-life-sciences-to-present-at-the-bio-international-convention.html
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Still a Buy?
May 28, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tiziana-life-sciences-nasdaqtlsa-stock-price-up-153-still-a-buy-2025-05-27/
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
May 23, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/tiziana-life-sciences-announces-interview-110000911.html
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease
May 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/23/3087399/0/en/tiziana-life-sciences-announces-interview-highlighting-intranasal-foralumab-for-the-treatment-of-moderate-alzheimer-s-disease.html
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
May 15, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/journal-clinical-nuclear-medicine-publishes-120000083.html
Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows
May 15, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1071307?snapi
Tiziana Life Sciences reports purchase of shares by chairman
May 12, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/tiziana-life-sciences-reports-purchase-of-shares-by-chairman/ar-AA1ECcO7
Tiziana Life Sciences Announces Purchase of Shares by Chairman
May 12, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/12/3078989/0/en/tiziana-life-sciences-announces-purchase-of-shares-by-chairman.html
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab
May 9, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1070973?snapi
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
May 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/09/3078109/0/en/tiziana-life-sciences-announces-significant-reduction-in-microglia-activation-in-pet-scan-of-moderate-alzheimer-s-patient-treated-with-intranasal-foralumab.html
Tiziana shares surge 21% on promising multiple sclerosis data
May 6, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1070747?snapi
Tiziana reports encouraging results for nasal MS drug in early study
May 6, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1070734?snapi
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
May 6, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/06/3074881/0/en/tiziana-life-sciences-announces-comprehensive-positive-results-from-study-of-nasal-foralumab-in-patients-with-multiple-sclerosis.html
Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 5.6% - Here's What Happened
April 23, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tiziana-life-sciences-nasdaqtlsa-shares-up-56-heres-what-happened-2025-04-21/
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts
April 23, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1070048?snapi
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
April 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/23/3066234/0/en/tiziana-life-sciences-announces-university-of-massachusetts-commences-dosing-intranasal-foralumab-in-phase-2-multiple-sclerosis-trial.html
Tiziana Life announces dosing at JHU, part of Phase 2 trial of foralumab
April 3, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tiziana-life-announces-dosing-at-jhu-part-of-phase-2-trial-of-foralumab-1034543138
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins
April 2, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1068999?snapi
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
April 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/02/3054204/0/en/tiziana-life-sciences-announces-johns-hopkins-university-commences-dosing-nasal-foralumab-in-phase-2-multiple-sclerosis-clinical-trial.html
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Rises By 42.5%
March 31, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-tiziana-life-sciences-ltd-nasdaqtlsa-rises-by-425-2025-03-30/
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS
March 25, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1068477?snapi
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
March 25, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/25/3048679/0/en/tiziana-life-sciences-announces-yale-university-commences-intranasal-foralumab-dosing-in-phase-2-multiple-sclerosis-trial.html
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
March 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/17/3043622/0/en/tiziana-life-sciences-to-present-at-the-37th-annual-roth-conference.html
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Down 39.2% in February
March 16, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tiziana-life-sciences-ltd-nasdaqtlsa-short-interest-down-392-in-february-2025-03-15/
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
March 14, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/14/3042966/0/en/tiziana-life-sciences-regains-compliance-with-nasdaq-listing-minimum-bid-price-rule.html
Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment
March 5, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4765017-tiziana-foralumab-drug-development-presses-on-with-additional-eap-enrollment
Tiziana submits FDA investigational new drug application
March 4, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1067324?snapi
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
March 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/04/3036470/0/en/tiziana-life-sciences-files-investigational-new-drug-application-with-fda-for-als-phase-2-clinical-trial.html
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short Interest
March 4, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tiziana-life-sciences-ltd-nasdaqtlsa-sees-significant-drop-in-short-interest-2025-03-04/
Tiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study reveals
February 27, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1067065?snapi
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
February 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/02/27/3033824/0/en/tiziana-life-sciences-announces-groundbreaking-study-published-in-nature-neuroscience-demonstrating-positive-results-for-nasal-anti-cd3-therapy-in-traumatic-brain-injury.html
Tiziana Life Sciences expects to complete Long Covid study in Q2
February 25, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tiziana-life-sciences-expects-to-complete-long-covid-study-in-q2-1034405089
Tiziana Life Sciences nearing completion of long COVID study on foralumab
February 25, 2025  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1066884?snapi
Get Tiziana Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TLSA Media Mentions By Week

TLSA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TLSA
News Sentiment
▼
1.31

0.97
▲
Average
Medical
News Sentiment

TLSA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TLSA Articles
This Week
▼
2

1
▲
TLSA Articles
Average Week

Get the Latest News and Ratings for TLSA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Tiziana Life Sciences and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:TLSA) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel